We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




US Supreme Court Mulls Patenting of Human Genes

By LabMedica International staff writers
Posted on 10 Dec 2012
The US Supreme Court (Washington DC, USA) will soon decide whether companies can patent human genes, which could reshape medical research and the fight against various diseases.

The case in question involves patents filed by Myriad Genetics (Salt Lake City, UT, USA) on two breast cancer (BRCA) predisposition genes for which the company has developed a specific test that identifies mutations on these genes that are associated with much greater risks of breast and ovarian cancer. More...
The American Civil Liberties Union (New York, NY, USA) challenged those patents, arguing that genes could not be patented, and in March 2010, a US district judge agreed and invalidated the patents, stating that “DNA's existence in an isolated form does not alter the fundamental quality of DNA as it exists in the body or the information it encodes.”

However, the US Federal Appeals Court reversed that decision in 2011, claiming Myriad's genes can be patented because the isolated DNA has a markedly different chemical structure from DNA within the body. Later on, the US Supreme Court invalidated that decision and sent the case back to the lower courts for rehearing. The decision came after the Supreme Court unanimously threw out patents on a Prometheus Laboratories (San Diego, CA, USA) test that assists doctors to set drug doses for autoimmune diseases like Crohn's disease, saying, “The laws of nature are unpatentable.”

However, in August 2012, the US Federal Circuit Court once again upheld Myriad's patents, leading to the current review. It is expected that in this round before the Supreme Court, the justices' decision will likely resolve an ongoing battle between scientists who believe that genes carrying the secrets of life should not be exploited for commercial gain, and companies that argue that a patent is a reward for years of expensive research that moves science forward.

“It's wrong to think that something as naturally occurring as DNA can be patented by a single company that limits scientific research and the free exchange of ideas,” said Chris Hansen, staff attorney with the ACLU Speech, Privacy and Technology Project.

Myriad’s company's lawyers responded, according to court papers, that without being able to patent and profit from their work, the company would not be able to fund the type of medical breakthroughs doctors depend on. The company also said that deciding now that genes cannot be patented would throw into chaos current research and profits structures for drug-makers, and medical research companies, who have been granted more than 40,000 DNA-related patents from the US Patent and Trademark Office in almost 30 years.

Related Links:

US Supreme Court
Myriad Genetics
Prometheus Laboratories



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.